Why the study?
Diabetic cardiomyopathy is the leading cause of death in diabetes, but drug molecules that alleviate diabetic cardiomyopathy severity while maintaining normoglycemia remain unexplored.
Do thiazolidinedione-pyrimidine hybrid compounds reduce blood glucose and improve markers of diabetic cardiomyopathy in STZ-NA induced diabetic Wistar rats?
Do thiazolidinedione-pyrimidine hybrid compounds reduce blood glucose and improve markers of diabetic cardiomyopathy in STZ-NA induced diabetic Wistar rats?
Novel thiazolidinedione-pyrimidine hybrid compounds show promise as antidiabetic agents with cardioprotective effects against diabetic cardiomyopathy in preclinical models.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for thiazolidinedione-pyrimidine hybrids in DCM models; leaves open clinical translation pending prospective trials.
The leading cause of death in diabetic patients is diabetic cardiomyopathy (DCM). Despite the availability of anti‐diabetic medications which effectively curb the hyperglycemia, the drug molecule which alleviates the severity of DCM along with the maintenance of a normoglycemic profile of diabetic patients is still unexplored. In this study, a series of thiazolidinedione‐pyrimidine hybrid compounds were synthesized, and their anti‐diabetic potential was explored in STZ‐NA induced diabetic Wistar rats. The role of these compounds in DCM was also evaluated. The most potent compound, PT‐5, showed significant reduction in blood glucose levels (from 129 to 115 mg/dL in 2 h) in comparison to the standard drug Pioglitazone (135–117 in 2 h). The biochemical estimations of AST, ALT, ALP, Troponin T, Cκ‐MB, CRP, and LDH levels illustrated that the levels appreciably came back to normal in the PT‐1, PT‐5, and PT‐13 treatment groups. The cardioprotective role was further validated by cardiac tropism indices and levels of antioxidants in cardiac tissue. The biochemical assessments were further validated through histopathological studies. This research indicates that these derivatives hold promise for the development of new potential antidiabetic agents.
No takes yet. Share an insight, caveat, or question.
Amin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: